{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31","upperLimit":"63","value":"47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Determine the efficacy of oral clofarabine (any of the 4 dose levels: 1mg, 2mg, 4mg, and 3mg) in all phase I trial patients with relapsed/refractory non-Hodgkin lymphomas.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","dispersionType":"90% Confidence Interval","groups":[{"description":"Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.","id":"OG000","title":"Phase I"}],"paramType":"MEAN","populationDescription":"Phase I participants only","reportingStatus":"POSTED","timeFrame":"after at most 6 28-day cycles","title":"Phase I Participants Only: Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}